Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Not yet recruiting · NCT07012980 · Registry updated 2025-06-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 2 | 2025-06-10 | NCT07012980 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BeiGene | 47 |
| Hoffmann-La Roche | 280 |
| Shanghai Zhongshan Hospital | 347 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||